Rep. Seth Moulton (D-MA) announced on April 22, 2019 that he was competing for the 2020 Democratic nomination and dropped out of the race on August 23.
An Iraq War veteran who has sponsored legislation to reform cannabis policies at the U.S. Department of Veterans Affairs (VA)—and who endorsed marijuana legalization prior to the voters of his state enacting it—the congressman earned a “B+” grade from NORML. Here’s a closer look at his record on cannabis.
This piece was last updated on August 29, 2019 to include the candidate’s statements and policy actions on marijuana since joining the race.
Legislation And Policy Actions
Moulton has been the chief sponsor of six marijuana-related bills, all of which focus on medical cannabis for military veterans.
During the 115th and 116th Congresses, he introduced bipartisan legislation that would require the VA to survey veterans about medical marijuana and another bill that would direct the department to provide training on cannabis to primary care physicians.
The congressman also filed a bill that would protect veterans from losing VA benefits due to marijuana use that’s in compliance with state law.
This week I introduced legislation that aims to reform VA medical marijuana practices. We should support our veterans who seek alternatives to highly addictive opioids ravaging our communities. https://t.co/sKhVY9rw3t
— TeamMoulton (@teammoulton) November 15, 2018
“Veterans want an alternative to opioids, and Congress should support them,” Moulton said in a press release about the package of bills. “Let’s not kid ourselves: people are using marijuana—including our veterans. Rather than ignoring this reality, Congress should let doctors talk with their patients about it, and we should learn more about cannabis so it can be safely used and properly regulated.”
“We have a long road ahead of us until medicinal cannabis is fully-researched and legal, but a few steps now will speed that along. Veterans deserve the best healthcare in the world,” he said. “This is a step in that direction.”
Outside of filing those bills, Moulton has signed on as a cosponsor of over a dozen other pieces of cannabis legislation, including bills that would remove marijuana from the list of federally controlled substances and exempt state-legal marijuana activity from the Controlled Substances Act (CSA).
Moulton has also cosponsored bipartisan bills that would shield banks that service state-legal marijuana businesses from being penalized by federal regulators and another to provide for tax fairness for the cannabis industry.
Other legislation he has signed onto would require the federal government to study the effects of state legalization laws, direct the VA conduct clinical trials on medical cannabis for veterans, shield federal employees from being fired for state-legal marijuana use and allow students to retain federal financial aid if they’re convicted of cannabis possession and complete a drug rehabilitation program.
He also cosponsored bills that would allow VA doctors to recommend medical cannabis for veterans and to require the Justice Department to approve additional marijuana manufacturer licenses for research purposes.
Legal marijuana companies lack access to banking – making it more difficult for states to track tax revenue and posing a threat to public safety. That's why I'm supporting @RepPerlmutter's SAFE Banking Act #HR2215. https://t.co/WXK1aSnaaU
— Seth Moulton (@sethmoulton) February 27, 2018
The first piece of marijuana legislation that Moulton cosponsored was the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, which would amend the CSA to protect medical marijuana patients and place cannabis in Schedule II.
In terms of votes on amendments, the congressman has a consistent track record of supporting reform on the House floor. In 2015, he voted in favor of amendments to protects states that have legalized marijuana for medical and recreational purposes, as well as states that have legalized CBD and industrial hemp. He also voted for amendments to allow VA doctors to recommend medical cannabis in 2015 and 2016.
On The Campaign Trail
Moulton wrote an op-ed for The Washington Examiner in which he advocated for legislation providing access to medical cannabis for veterans.
“There are places we have to strictly enforce drug laws and places we need to liberalize them, but there’s no question that the vast majority of cities and countries that have decriminalized drugs have seen an improvement in their addicted populations,” he said. “It’s time for change.”
“Ultimately, making the VA a place where veterans can discuss and maybe someday access cannabis, will help our country evolve on this issue too. Through that evolution, I believe we will be able to tackle bigger challenges together—like ending the fundamentally-unjust process of locking people up for possessing marijuana, and, in effect, sentencing them to a lifetime of fewer job opportunities. I support releasing people who are in jail for marijuana possession and expunging their records, especially because Americans in more than half the states in the nation voted to decriminalize this.”
He included adopting a “holistic approach to treatment, including alternative therapies like mindfulness, exercise, & cannabis” in a mental health plan he released in May 2019.
—Make mental health check-ups as routine as physicals for active-duty military & veterans
—Require mandatory counseling for everyone returning from a combat deployment
—Adopt a holistic approach to treatment, including alternative therapies like mindfulness, exercise, & cannabis
— Seth Moulton (@sethmoulton) May 28, 2019
The same month, Moulton said that people in prison for marijuana should be released and have their records expunged.
The congressman said that when he was enlisting in the Marines, he was asked about his cannabis use and that he was privileged to have been accepted after telling the truth that he did previously consume marijuana while others may be denied. He made the admission while advocating for an amendment that would provide military reenlistment waivers for those who only used marijuana once, which cleared a congressional committee in March and was later approved by the full House.
“I’ve seen the statistics of how unbelievably unjust these laws are applied,” he told Business Insider in June 2019 while discussing racial disparities in marijuana enforcement.
“Our criminal justice system is historically unfair,” he tweeted. “One thing we can do to address it is legalize marijuana and make sure those with minor marijuana offenses—who are overwhelmingly people of color—have their records cleared.”
Our criminal justice system is historically unfair. One thing we can do to address it is legalize marijuana and make sure those with minor marijuana offenses—who are overwhelmingly people of color—have their records cleared. pic.twitter.com/CUpUPJLRFW
— Seth Moulton (@sethmoulton) June 20, 2019
Moulton also delivered a keynote address via video for a cannabis conference.
The congressman told The Boston Globe that he is open to decriminalizing drugs beyond cannabis and that he supports legalizing safe injection sites where people can use illicit drugs like heroin in a medically supervised environment.
“There are places we have to strictly enforce drug laws and places we need to liberalize them, but there’s no question that the vast majority of cities and countries that have decriminalized drugs have seen an improvement in their addicted populations,” he said.
In an interview with Newsy, Moulton said that he is “absolutely open to exploring” legalizing drugs like psilocybin but that more research is needed.
“This is part of our job in Congress is, rather than being black and white about these issues when we don’t even understand the facts, this is a good example of something where I just need to learn the facts and understand more about it,” he said.
Previous Quotes And Social Media Posts
Moulton isn’t especially prolific when it comes to talking about marijuana on social media as compared to some other candidates, but what he has said bodes well for reform advocates.
Importantly, he publicly endorsed Massachusetts’s cannabis legalization measure ahead of Election Day in 2016—something that fellow 2020 contender Sen. Elizabeth Warren (D-MA) declined to do.
“I support legalization, but we do need to make sure it’s done right,” he said at the time. “We have an obligation to regulate it and make it as safe as possible.”
“One of the advantages of legalization is it will force us to come to terms with things already happening in Massachusetts today, like people driving under the influence of marijuana and kids using it,” he told WBGH. “If you’re not buying your marijuana from a dealer who sells heroin, who sells opioids, it’s much less likely to be a gateway drug. The problem is now that it operates in the shadows.”
After voters approved the legalization initiative, Moulton said that the state legislature should “dramatically raise the taxes” on marijuana to raise revenue and help fund law enforcement efforts, and he said there’s “a lot of work to be done” that “needs to start right away.”
“There’s a lot that the state legislature needs to do,” Moulton said. “My whole reason for endorsing this was that we’ve got to bring marijuana out of the shadows and actually regulate it. That’s up to the state legislature. So I think this is an important step in the right direction because, let’s not kid ourselves, people were getting access to marijuana today and they were getting access to it yesterday as well.”
Moulton often talks about bringing cannabis “out of the shadows” so that it can be regulated. And he criticized the lack of operating dispensaries in Massachusetts, observing that cannabis will still be sold and consumed in jurisdictions that aren’t allowing the shops.
“The reality is, we’re not going to make marijuana go away by pretending that it’s not in our community,” he said in 2018. “What we ought to be doing is figuring out ways to regulate its use responsibly because otherwise it’s going to be used in the shadows.”
“It’s not my role as a United States representative to come and tell Peabody what to do, but I’m certainly entitled to my opinion and that is my view of this issue,” he said. “I think we’ve got to wake up to the world that we’re in and be responsible about regulating these substances that are a part of our community—and can be used safely, if used appropriately—rather than outlawing them and pretending that they’re not going to be here at all.”
The congressman also applauded the Salem for accepting marijuana businesses, saying that the city was “leading the way.”
MA's 1st medical marijuana dispensary opened in Salem on Weds – a big step for those suffering from painful diseases. http://t.co/Pjnat7dx5v
— Seth Moulton (@sethmoulton) June 27, 2015
“I think the demand that we see proves what I have said all along: People are using marijuana and they want to use it legally, and we should allow them to use it legally and safely with the proper regulation, rather than pretend by outlawing it, people are going to stop,” he said.
Speaking about legislation he filed with respect to veterans and marijuana, Moulton said in 2018 that “it’s clear that this is where things are going” and noted his support for Massachusetts’s legalization initiative. He said “we need to realize people are going to use marijuana whether we like it or not, so let’s make it legal and let’s regulate it to make it safe.”
While testing the waters in the primary state of Iowa in March 2019, Moulton talked about his support for cannabis decriminalization and said that it can help veterans suffering from post-traumatic stress disorder and also serve as an alternative to opioid painkillers.
Marijuana May Alleviate America’s Opioid Crisis. My view: Legalization & regulation can help but we must be careful. https://t.co/0X0a8ZjWYo
— Seth Moulton (@sethmoulton) September 24, 2016
He also talked about his veterans bills on the Cannabis Economy podcast, saying he and fellow sponsor Rep. Matt Gaetz (R-FL) “want to make it very clear to everybody—to veterans, to healthcare providers—that if you’re using cannabis, you should talk about it.”
We shouldn’t kid ourselves – veterans use marijuana. We have an obligation to make it safe, regulate it, and protect the benefits of vets who would like to discuss it with their doctors. @mattgaetz and I intro’d legislation that would do all of the above. https://t.co/XctzfJq9gk
— Seth Moulton (@sethmoulton) January 30, 2019
“You should be able to have an honest, transparent conversation with your healthcare provider so that they can give you better health care,” he said.
Moulton criticized then-Attorney General Jeff Sessions after he rescinded Obama-era guidance on federal marijuana enforcement priorities.
This is the opposite of what we should be doing. Let’s not kid ourselves – people will be using marijuana regardless of what Attorney General Sessions says. We have an obligation to regulate it and make it as safe as possible.
— Seth Moulton (@sethmoulton) January 4, 2018
“This is the opposite of what we should be doing. Let’s not kid ourselves—people will be using marijuana regardless of what Attorney General Sessions says,” he wrote. “We have an obligation to regulate it and make it as safe as possible.”
His House reelection campaign subsequently put out a survey claiming that the Trump administration “wants to crack down on possession—hurting those in need of medicinal marijuana and putting new businesses in jeopardy” and posed the question: “do you think the Trump Administration should be interfering with states marijuana laws?”
Personal Experience With Marijuana
Moulton said he has tried marijuana “a couple times” while he was a student at Harvard University, but he added that he “certainly didn’t qualify as a pothead.”
In March 2019, the congressman said “I’ve used weed, and I’m not in prison.”
Seth Moulton asked about marijuana laws: "I've used weed, and I'm not in prison. Why? Because I didn't get caught, and it probably doesn't hurt that I'm white. That's the sad reality of criminal justice in America today."
— Dave Weigel (@daveweigel) March 19, 2019
“Why? Because I didn’t get caught, and it probably doesn’t hurt that I’m white,” he said. That’s the sad reality of criminal justice in America today.”
One month later, he repeated that point during a CNN town hall event.
“I smoked weed when I was younger,” he said. “I didn’t get caught, but if I had, I would’ve been fine. Because I’m a white guy.”
Marijuana Under A Moulton Presidency
Moulton has made marijuana reform—particularly for veterans seeking medical cannabis—somewhat of a priority during his time in Congress. He hasn’t added his name as a cosponsor to broad, equity-focused bills like the Marijuana Justice Act, but he has repeatedly said that the country should regulate cannabis sales to bring it out of the shadows.
And having endorsed the legalization measure in Massachusetts prior to its approval by voters in 2016, Moulton would be in a position to take similar leadership on the issue if elected president.
Kansas Medical Marijuana Hearings Cancelled After Senate GOP Leader Reroutes House-Passed Bill
A House-passed bill to legalize medical marijuana in Kansas seems to be in jeopardy, with GOP Senate leadership moving the legislation out of a committee and into a different panel where it may sit in legislative limbo, resulting in the cancellation of hearings that were scheduled to be held this week.
Advocates are concerned about the decision by Senate President Ty Masterson (R), who withdrew the cannabis reform legislation from the Senate Federal and State Affairs Committee days before hearings were to be held on Tuesday and Wednesday. It was then re-referred to the Senate Interstate Cooperation Committee, which Masterson chairs and where the bill’s fate is unclear.
This doesn’t necessarily mean that medical marijuana legalization is off the table for Kansas in 2022, but it does seem to signal that the reform might need to be enacted through another vehicle, either in the legislature or at the ballot, as top Democratic lawmakers in the state are pursuing.
“We certainly hope that this action is just making sure that this bill meets any concerns that Senate leadership may have concerning this historic legislation,” Kevin Caldwell, a legislative manager at Marijuana Policy Project (MPP), told Marijuana Moment. “This bill had widespread bipartisan support in the House last session. We hope Senate President Masterson quickly holds a committee hearing and advances this legislation.”
When the proposal was being advanced in the House last year during the first half of the two-year session, members amended an unrelated bill that previously cleared the Senate to make it the chamber’s vehicle for the policy change. Because of that, it was ruled “materially changed” last May and sent to the Senate for committee consideration.
Now there’s a question of whether lawmakers will be motivated to introduce another separate bill and try to move it through both chambers, requiring another House vote. The Senate president seemed to temper expectations in recent remarks, telling The Kansas City Star that “not a single member” of his caucus has expressed that the issue “was important to them.”
That’s not how Kansas Democrats feel, however. House Minority Leader Tom Sawyer (D) and Assistant Minority Leader Jason Probst (D) said this month that they will be introducing proposals to let voters decide on legalizing medical and adult-use marijuana in the state. At the time, Sawyer said he was “hopeful” that the legislature might separately advance the House-passed legalization measure.
Marijuana Moment is already tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
“The people of Kansas deserve to know if senators support the overwhelming majority of people who want to alleviate patients’ suffering with a medical cannabis program,” MPP’s Caldwell said. “Now is the time to show compassion to their fellow citizens and vote this bill out of committee.”
“Kansas is one of fourteen states left without a medical cannabis program,” he said. “We have faith that the Kansas Senate will pass this legislation this session and this is just another step in that process.”
Michael Pirner, Masterson’s communications director, told the Star that “medical marijuana legislation is not a priority of Senate leadership,” but did signal the issue may still be considered before the year is over.
“The subject matter has clearly matured and we expect it to be considered at some level this session,” he said. “There are many more pressing topics on the Senate agenda.”
The bill as drafted contains several significant restrictions, including a ban on smokeable cannabis. Members of the Senate Federal and State Affairs Committee did get a briefing on the issue at a meeting last week ahead of the expected, now-cancelled formal hearings before the panel.
Meanwhile, the constitutional amendment that the Democratic leaders are proposing would provide for a more comprehensive program that lawmakers would need to implement.
Gov. Laura Kelly (D), for her part, wants to see medical cannabis legalization enacted, and she said at a briefing with reporters on Friday that she “absolutely” thinks the bill could pass if “everything else doesn’t take up all the oxygen.”
She previously pushed a separate proposal that would legalize medical cannabis and use the resulting revenue to support Medicaid expansion, with Rep. Brandon Woodard (D) filing the measure on the governor’s behalf.
Kelly has she said she wants voters to put pressure on their representatives to get the reform passed.
The governor also said in 2020 that while she wouldn’t personally advocate for adult-use legalization, she wouldn’t rule out signing the reform into law if a reform bill arrived on her desk.
Photo courtesy of Philip Steffan.
Marijuana Banking Bill Sponsor Says He’s ‘Gonna Get That Darn Thing Passed’ Before Leaving Office
Rep. Ed Perlmutter (D-CO) is retiring from Congress at the end of this session, but he says that he’s going to work to pass his marijuana banking bill before his time on Capitol Hill comes to an end.
The congressman spoke to Colorado Public Radio last week about his decision not to run for reelection this November and his disappointment that, while the House has approved the Secure and Fair Enforcement (SAFE) Banking Act five times now in some form, the Senate has failed to advance it under both Republican and Democratic leadership.
“That one still has me pretty irritated,” Perlmutter said, referring to the fact that Senate Majority Leader Chuck Schumer (D-NY) has effectively blocked his bipartisan legislation. When there was a GOP Senate majority, he was told the bill was “too big and too broad.” Then with a Democratic majority, he’s told that it’s “too narrow and too limited.”
Schumer and his colleagues who are working on a federal legalization bill have repeatedly said that they do not want to see the SAFE Banking Act pass before comprehensive reform is enacted that addresses equity issues. Supporters of the banking bill argue that the incremental policy change is necessary for promote public safety and, importantly, it stands a much stronger chance of getting to the president’s desk with bipartisan support.
Nonetheless, Perlmutter said he plans to spend his remaining months in office pushing to get the job done.
“I have not given up on that one,” he said. “I’m gonna get that darn thing passed this year while I still serve out my term.”
Listen to Perlmutter discuss the marijuana banking legislation, starting around 10:24 into the audio below:
Asked whether he thinks President Joe Biden would be inclined to sign the measure if it did get to his desk, the congressman said “absolutely.”
“Treasury Secretary [Janet] Yellen is somebody who has been talking to me about this for years,” he said. “I feel very good that it would pass. We’re at 47 states that have some level of marijuana use, all the territories and District of Columbia, and they need to have legitimate banking services.”
“It’s just a no brainer in my opinion,” he said. “And yeah, I’m a little bit irritated, but we’re gonna keep working on it and get it passed this year.”
The last attempt that Perlmutter made to enact the reform was by adding its language to a must-pass defense bill, but it was ultimately sidelined following bicameral negotiations and did not make it into the final version. The congressman told Marijuana Moment last month that he sees other potential vehicles to advance the bill and has spoken with House Speaker Nancy Pelosi (D-CA) about it.
Even some Republicans are scratching their heads about how Democrats have so far failed to pass the modest banking reform with majorities in both chambers and control of the White House. For example, Rep. Rand Paul (R-KY) criticized his Democratic colleagues over the issue last month.
Top Federal Drug Official Says ‘Train Has Left The Station’ On Psychedelics As Reform Movement Spreads
A top federal drug official says the “train has left the station” on psychedelics.
National Institute on Drug Abuse (NIDA) Director Nora Volkow said people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn to the potential therapeutic benefits—and so researchers and regulators will need to keep up.
The comments came at a psychedelics workshop Volkow’s agency cohosted with the National Institute of Mental Health (NIMH) last week.
The NIDA official said that, to an extent, it’s been overwhelming to address new drug trends in the psychedelics space. But at the same time, she sees “an incredible opportunity to also modify the way that we are doing things.”
“What is it that the [National Institutes of Health] can do to help accelerate research in this field so that we can truly understand what are the potentials, and ultimately the application, of interventions that are bought based on psychedelic drugs?” Volkow said.
The director separately told Marijuana Moment on Friday in an emailed statement that part of the challenge for the agency and researchers is the fact that psychedelics are strictly prohibited as Schedule I drugs under the federal Controlled Substances Act.
“Researchers must obtain a Schedule I registration which, unlike obtaining registrations for Schedule II substances (which include fentanyl, methamphetamine, and cocaine), is administratively challenging and time consuming,” she said. “This process may deter some scientists from conducting research on Schedule I drugs.”
“In response to concerns from researchers, NIDA is involved in interagency discussions to facilitate research on Schedule I substances,” Volkow said, adding that the agency is “pleased” the Drug Enforcement Administration recently announced plans to significantly increase the quota of certain psychedelic drugs to be produced for use in research.
“It will also be important to streamline the process of obtaining Schedule I registrations to further the science on these substances, including examining their therapeutic potential,” she said.
At Thursday’s event, the official talked about how recent, federally funded surveys showed that fewer college-aged adults are drinking alcohol and are instead opting for psychedelics and marijuana. She discussed the findings in an earlier interview with Marijuana Moment as well.
Don't miss out on the @NIDAnews, @NIAAAnews, & @NIMHgov-sponsored virtual Workshop on Psychedelics as Therapeutics: Gaps, Challenges, and Opportunities, Jan. 12‒13, 2022. Learn more and register: https://t.co/S1zttkoYXq pic.twitter.com/C2Qrk6FN9a
— NIDAnews (@NIDAnews) January 10, 2022
“Let’s learn from history,” she said. “Let’s see what we have learned from the marijuana experience.”
While studies have found that marijuana use among young people has generally remained stable or decreased amid the legalization movement, there has been an increase in cannabis consumption among adults, she said. And “this is likely to happen [with psychedelics] as more and more attention is placed on these psychedelic drugs.”
“I think, to a certain extent, with all the attention that the psychedelic drugs have attracted, the train has left the station and that people are going to start to use it,” Volkow said. “People are going to start to use it whether [the Food and Drug Administration] approves or not.
There are numerous states and localities where psychedelics reform is being explored and pursued both legislatively and through ballot initiative processes.
On Wednesday—during the first part of the two-day federal event that saw nearly 4,000 registrants across 21 time zones—NIMH Director Joshua Gordon stressed that his agency has “been supporting research on psychedelics for some time.”
Tune in today and tomorrow for the @NIH workshop on Psychedelics as Therapeutics, which will examine findings on psychoplastogens for treating depression, post-traumatic stress, and substance and alcohol use disorders. https://t.co/Qzxte5xJt9
— Joshua A. Gordon (@NIMHDirector) January 12, 2022
“We can think of NIMH’s interests in studying psychedelics both in terms of proving that they work and also in terms of demonstrating the mechanism by which they work,” he said. “NIMH has a range of different funding opportunity announcements and other expressions that are priorities aimed at a mechanistic focus and mechanistic approach to drug development.”
Meanwhile, Volkow also made connections between psychedelics and the federal response to the coronavirus pandemic. She said, for example, that survey data showing increased use of psychedelics “may be a way that people are using to try to escape” the situation.
But she also drew a metaphor, saying that just as how the pandemic “forced” federal health officials to accelerate the development and approval of COVID-19 vaccines because of the “urgency of the situation,” one could argue that “actually there is an urgency to bring treatments [such as emerging psychedelic medicines] for people that are suffering from severe mental illness which can be devastating.”
But as Volkow has pointed out, the Schedule I classification of these substances under federal law inhibits such research and development.
The official has also repeatedly highlighted and criticized the racial disparities in drug criminalization enforcement overall.